AlcoChange:为患有与酒精有关的肝脏疾病的患者提供数字治疗
Gautam Mehta1,2,3, Su Lin1,4, Aida Nadar1
1Institute for Liver and Digestive Health, University College London, London, UK.
JHEP reports : innovation in hepatology
|March 1, 2024
概括
一种新的数字治疗方法AlcoChange显著减少了酒精消费,并增加了与酒精有关的肝病 (ARLD) 患者的戒断率. 这项技术有望预防ARLD并发症.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 数字治疗学数字治疗学
- 行为科学 行为科学
背景情况:
- 与酒精有关的肝病 (ARLD) 是一个重大的全球健康挑战.
- 保持禁欲对于管理ARLD至关重要,但有效的治疗选择有限.
- 数字疗法提供了一种可扩展的方法,用于为慢性疾病提供实时行为疗法.
研究的目的:
- 开发和临床评估AlcoChange,一种用于ARLD的新型数字治疗干预.
- 评估AlcoChange在减少ARLD患者的酒精消费和促进戒断方面的有效性.
主要方法:
- 一项开放的,单中心的研究,涉及ARLD患者和最近的酒精使用.
- AlcoChange疗法,包括行为改变技术和数字呼吸分析仪,进行了3个月.
- 主要结果:减少酒精使用;次要结果:应用程序合规性,医院再入院,以及影响合规性的定性因素.
主要成果:
- 与非合规患者相比,合规患者 (>60登录) 的酒精使用显著减少 (p=0.029).
- 在3个月后,在合规组中观察到更高的戒断率 (57.1%对22.2%,p=0.025).
- 合规与与酒精有关的再入院减少有关,并通过应用内反和哨兵事件进行预测.
结论:
- 在ARLD患者中,AlcoChange数字治疗与显著减少酒精使用和增加禁欲有关.
- 数字疗法可能在ARLD的预防和管理中发挥作用.
- 通过最终随机对照试验进行进一步验证是有必要的.
相关概念视频
01:27CNS Depressants: Alcohol and Nicotine
207
Ethanol, a clear colorless alcohol, has been consumed by humans for millennia, but its effects on the body are far from benign. At lower doses, it induces decreased inhibitions and loquaciousness, leading to its social appeal. However, it can cause severe consequences at higher doses, such as coma and respiratory depression, due to its zero-order elimination kinetics. Chronic ethanol abuse wreaks havoc on multiple organ systems, particularly the CNS and the liver. Abrupt cessation of ethanol...
207
02:23Alcohols from Carbonyl Compounds: Reduction
10.4K
Reduction is a simple strategy to convert a carbonyl group to a hydroxyl group. The three major pathways to reduce carbonyls to alcohols are catalytic hydrogenation, hydride reduction, and borane reduction.
Catalytic hydrogenation is similar to the reduction of an alkene or alkyne by adding H2 across the pi bond in the presence of transition metal catalysts like Raney Ni, Pd–C, Pt, or Ru. Aldehydes and ketones can be reduced by this method, often under mild to moderate heat (25–100°C) and...
Catalytic hydrogenation is similar to the reduction of an alkene or alkyne by adding H2 across the pi bond in the presence of transition metal catalysts like Raney Ni, Pd–C, Pt, or Ru. Aldehydes and ketones can be reduced by this method, often under mild to moderate heat (25–100°C) and...
10.4K
01:29Chronic Pancreatitis II: Collaborative Care
88
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
88
02:48Conversion of Alcohols to Alkyl Halides
7.2K
This lesson delves into the conversion of alcohols to corresponding alkyl halides and the mechanism of action for different reagents. Typically, the hydroxyl group is first protonated to convert it to a stable leaving group. Consequently, based on the starting alcohol, the mechanism undergoes either of the nucleophilic substitution routes, SN1 or SN2. Tertiary alkyl halides are made using the two-step SN1 mechanism that occurs via a carbocation intermediate, which is stabilized by...
7.2K
02:00Alcohols from Carbonyl Compounds: Grignard Reaction
5.5K
Grignard reagents are one of the most commonly used reagents used to synthesize alcohols from carbonyl compounds. Grignard reagents are organomagnesium halides with a highly polar carbon–magnesium bond. Due to the partial ionic nature of the C–Mg bond, the carbon functions as a strong nucleophile and attacks electrophiles like carbonyl carbon.
Magnesium from the reagent coordinates with carbonyl oxygen, further reducing the carbonyl carbon's electron density. Thus, the...
Magnesium from the reagent coordinates with carbonyl oxygen, further reducing the carbonyl carbon's electron density. Thus, the...
5.5K
01:22Alzheimer's Disease: Treatment
188
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
188